Business Context and Reporting Period
Company: Nephros, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: April 7, 2016
Subject: Resolution of FDA Warning Letter regarding facility inspections.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding regulatory compliance and does not contain financial statements. The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material event is the receipt of a letter from the U.S. Food and Drug Administration (FDA) on April 7, 2016. This letter confirms that the FDA has completed its evaluation of the Company's corrective actions in response to a Warning Letter issued on May 27, 2015. The FDA determined that the Company has addressed the violations cited in the original Warning Letter.
Outlook, Risks, and Management Commentary
- Regulatory Status: The FDA's evaluation indicates the violations from the 2015 Warning Letter have been addressed.
- Operational Impact: Neither the original Warning Letter nor subsequent correspondence restricted the manufacture, production, or shipment of products, nor did they require product withdrawals.
- Recent Inspection: An FDA on-site inspection in February 2016 resulted in no observations or Form 483 citations.
- Corrective Actions: The Company revised standard operating procedures regarding purchasing, supplier controls, adverse event reporting, and complaint handling.
Investor Verification Checklist
- Verify the full text of the FDA "Third Letter" attached as Exhibit 99.1 to confirm the scope of the resolution.
- Confirm that no new regulatory actions or inspections are pending following the February 2016 inspection.
- Review subsequent quarterly reports (10-Q) or annual reports (10-K) for any financial impact related to the costs of implementing corrective actions.
- Monitor future FDA inspection schedules to ensure continued compliance.